ATE264911T1 - Eine universelle immunmodulatorische cytokin- expressierende zelllinie in wartestelling. entsprechende zusammensetzungen und methoden ihrer herstellung und verwendungen - Google Patents

Eine universelle immunmodulatorische cytokin- expressierende zelllinie in wartestelling. entsprechende zusammensetzungen und methoden ihrer herstellung und verwendungen

Info

Publication number
ATE264911T1
ATE264911T1 AT99905651T AT99905651T ATE264911T1 AT E264911 T1 ATE264911 T1 AT E264911T1 AT 99905651 T AT99905651 T AT 99905651T AT 99905651 T AT99905651 T AT 99905651T AT E264911 T1 ATE264911 T1 AT E264911T1
Authority
AT
Austria
Prior art keywords
cell line
waiting
preparation
methods
expressing cell
Prior art date
Application number
AT99905651T
Other languages
English (en)
Inventor
Hyam I Levitsky
Ivan Borrello
Original Assignee
Univ Johns Hopkins Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med filed Critical Univ Johns Hopkins Med
Application granted granted Critical
Publication of ATE264911T1 publication Critical patent/ATE264911T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT99905651T 1998-02-02 1999-02-02 Eine universelle immunmodulatorische cytokin- expressierende zelllinie in wartestelling. entsprechende zusammensetzungen und methoden ihrer herstellung und verwendungen ATE264911T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7340598P 1998-02-02 1998-02-02
PCT/US1999/002253 WO1999038954A1 (en) 1998-02-02 1999-02-02 A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use

Publications (1)

Publication Number Publication Date
ATE264911T1 true ATE264911T1 (de) 2004-05-15

Family

ID=22113512

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99905651T ATE264911T1 (de) 1998-02-02 1999-02-02 Eine universelle immunmodulatorische cytokin- expressierende zelllinie in wartestelling. entsprechende zusammensetzungen und methoden ihrer herstellung und verwendungen

Country Status (10)

Country Link
US (5) US6464973B1 (de)
EP (1) EP1053301B1 (de)
JP (1) JP4303887B2 (de)
KR (1) KR20010074426A (de)
AT (1) ATE264911T1 (de)
AU (1) AU741602B2 (de)
CA (1) CA2318372C (de)
DE (1) DE69916581T2 (de)
ES (1) ES2218994T3 (de)
WO (1) WO1999038954A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE264911T1 (de) * 1998-02-02 2004-05-15 Univ Johns Hopkins Med Eine universelle immunmodulatorische cytokin- expressierende zelllinie in wartestelling. entsprechende zusammensetzungen und methoden ihrer herstellung und verwendungen
US7745140B2 (en) * 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US7638326B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
US7638325B2 (en) * 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
EP1374893A1 (de) 2002-06-17 2004-01-02 NovImmune S.A. Impfung mit Immuno-isolierten Zellen die einen Immunomodulator Produzieren
AU2003270823A1 (en) * 2002-09-19 2004-04-08 Johns Hopkins University School Of Medicine Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine
US7176022B2 (en) 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
US7498024B2 (en) * 2003-06-03 2009-03-03 Cell Genesys, Inc. Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
US20050186178A1 (en) * 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
SI1523991T1 (sl) * 2003-10-18 2014-07-31 Alind & Kraja Sha Cepivo proti raku
CA2568344C (en) 2004-05-27 2016-01-19 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
US20060062764A1 (en) * 2004-08-25 2006-03-23 Seshidar-Reddy Police Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
US20060057127A1 (en) * 2004-09-10 2006-03-16 Pocheng Liu Cytokine-expressing cellular vaccines for treatment of prostate cancer
WO2007123737A2 (en) 2006-03-30 2007-11-01 University Of California Methods and compositions for localized secretion of anti-ctla-4 antibodies
US20070231298A1 (en) * 2006-03-31 2007-10-04 Cell Genesys, Inc. Cytokine-expressing cancer immunotherapy combinations
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
US20090311226A1 (en) * 2006-05-22 2009-12-17 The John Hopkins University Composition and method for treating esophageal dysplasia
US7901902B2 (en) 2006-07-27 2011-03-08 Biosante Pharmaceuticals, Inc. Methods and compositions for identifying a cellular immune response against prostate cancer
EP2132324B1 (de) * 2007-03-02 2012-04-25 Biosante Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur identifizierung von prostatakrebs oder einer humoralen immunantwort gegen prostatakrebs
WO2008124102A2 (en) * 2007-04-06 2008-10-16 Cell Genesys Inc. Ara-c in combination with a cytokine-secreting cell and use thereof
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
US8425897B2 (en) * 2007-08-30 2013-04-23 Immutep S.A. Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use
US20110038801A1 (en) * 2007-12-21 2011-02-17 Biosante Pharmaceuticals, Inc. Methods and compositions for identifying lung cancer or a humoral immune response against lung cancer
EP2320791B1 (de) * 2008-06-06 2016-08-31 Covidien LP Systeme zur beatmung in relation zur anstrengung des patienten
US8840881B2 (en) * 2008-08-28 2014-09-23 Aduro Gvax Inc. Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer
WO2010062742A2 (en) * 2008-11-03 2010-06-03 The Johns Hopkins University Methods for freparation and use of marrow infiltrating lymphocytes (mils)
EP2531216B1 (de) 2010-02-04 2019-03-27 The Trustees Of The University Of Pennsylvania Icos zur kritischen regulierung der expansion und funktion entzündlicher menschlicher th17-zellen
JP6042802B2 (ja) 2010-04-27 2016-12-14 ザ・ジョンズ・ホプキンス・ユニバーシティ 新生物（腫瘍）を治療するための免疫原性組成物及び方法。
JP5849710B2 (ja) * 2011-02-03 2016-02-03 セントラル硝子株式会社 β−フルオロアルコール類の製造方法
WO2013185052A1 (en) 2012-06-08 2013-12-12 Aduro Biotech Compostions and methods for cancer immunotherapy
EA201590396A1 (ru) 2012-12-13 2015-12-30 Адуро Биотек, Инк. Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения
SG11201505858VA (en) 2013-01-28 2015-09-29 St Jude Childrens Res Hospital A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
EP2991655B1 (de) 2013-04-29 2024-04-10 Memorial Sloan Kettering Cancer Center Zusammensetzungen und verfahren zur veränderung der signalisierung sekundärer botenstoffe
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
EP3653637A1 (de) 2013-05-18 2020-05-20 Aduro BioTech, Inc. Zusammensetzungen und verfahren zur aktivierung einer vom stimulator der interferon-genen abhängigen signalisierung
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
AU2015259877B2 (en) 2014-05-15 2021-02-25 National University Of Singapore Modified natural killer cells and uses thereof
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
WO2016145102A1 (en) 2015-03-10 2016-09-15 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
EP3352783B1 (de) 2015-09-25 2021-08-25 MaxiVAX SA Impfstoff, der einen immunomodulator produzierende immunoisolierte zellen enthält
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018182511A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
CN117384929A (zh) 2017-03-27 2024-01-12 新加坡国立大学 一种编码由细胞表达的嵌合受体的多核苷酸
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CN113766956B (zh) 2019-03-05 2024-05-07 恩卡尔塔公司 Cd19定向性嵌合抗原受体及其在免疫疗法中的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744347A (en) 1987-01-16 1998-04-28 Ohio University Edison Biotechnology Institute Yolk sac stem cells and their uses
US5705732A (en) 1989-06-12 1998-01-06 Oklahoma Medical Research Foundation Universal donor cells
US5574205A (en) * 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
EP0950707B1 (de) 1989-07-25 2009-02-18 Cell Genesys, Inc. Homologe Rekombination für universelle Donorzellen und chimerische Säugetierzellen
US5681562A (en) * 1991-06-25 1997-10-28 Sidney Kimmel Cancer Center Lymphokine gene therapy of cancer
US5674486A (en) * 1991-06-25 1997-10-07 San Diego Regional Cancer Center Cancer immunotherapy with carrier cells
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
CA2121487A1 (en) 1991-10-21 1993-04-29 Stephen A. Sherwin Combined cellular and immunosuppresive therapies
ES2144426T3 (es) * 1991-10-25 2000-06-16 Sidney Kimmel Cancer Ct Terapia genica linfoquimica del cancer en combinacion con antigenos tumorales.
FR2683725B1 (fr) * 1991-11-15 1995-07-07 Pasteur Institut Composition cellulaire pour le traitement des organismes humains ou animaux.
AU676204B2 (en) * 1992-09-18 1997-03-06 Canji, Inc. Gene therapy by retroviral vector with tumor suppressive gene
CA2178902A1 (en) * 1993-12-14 1995-06-22 Drew Pardoll Controlled release of pharmaceutically active substances for immunotherapy
WO1996033746A1 (en) 1995-04-28 1996-10-31 Genetic Therapy, Inc. Treatment of tumors with cells expressing interferons, tumor necrosis factors, or other cytokines
DE19541450C2 (de) * 1995-11-07 1997-10-02 Gsf Forschungszentrum Umwelt Genkonstrukt und dessen Verwendung
DE19608751B4 (de) * 1996-03-06 2006-05-18 Medigene Ag Verwendung eines Adeno-assoziierten Virus-Vektors zur Steigerung der Immunogenität von Zellen
ATE264911T1 (de) * 1998-02-02 2004-05-15 Univ Johns Hopkins Med Eine universelle immunmodulatorische cytokin- expressierende zelllinie in wartestelling. entsprechende zusammensetzungen und methoden ihrer herstellung und verwendungen

Also Published As

Publication number Publication date
JP4303887B2 (ja) 2009-07-29
US7390483B2 (en) 2008-06-24
CA2318372A1 (en) 1999-08-05
KR20010074426A (ko) 2001-08-04
US8012469B2 (en) 2011-09-06
EP1053301B1 (de) 2004-04-21
JP2002501741A (ja) 2002-01-22
CA2318372C (en) 2008-08-19
DE69916581D1 (de) 2004-05-27
WO1999038954A1 (en) 1999-08-05
US20020037282A1 (en) 2002-03-28
US6464973B1 (en) 2002-10-15
US20060140922A1 (en) 2006-06-29
AU2576499A (en) 1999-08-16
DE69916581T2 (de) 2004-09-16
US20080260758A1 (en) 2008-10-23
EP1053301A1 (de) 2000-11-22
ES2218994T3 (es) 2004-11-16
US20110287058A1 (en) 2011-11-24
AU741602B2 (en) 2001-12-06

Similar Documents

Publication Publication Date Title
ATE264911T1 (de) Eine universelle immunmodulatorische cytokin- expressierende zelllinie in wartestelling. entsprechende zusammensetzungen und methoden ihrer herstellung und verwendungen
AU1593001A (en) Recombinant gelatin in vaccines
EP2330129A3 (de) Antikörper gegen TNF, Zusammensetzungen, Verfahren und Verwendungen
ATE481108T1 (de) Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen
IL127558A0 (en) Hepatocyte growth factor receptor agonists and uses thereof
AP2001002225A0 (en) 1-heterocycle substituted diarylamines.
AU4981101A (en) Subtilisin variants
ES2300276T3 (es) P40 de interleuquina-12 de mamifero e interleuquina b30. sus combinaciones. anticuerpos. usos en composiciones farmaceuticas.
EP1032417A4 (de) Bakterielle impfstoffe, enthaltend auxotrophe verzögerte listeria stämme, welche heterologe antigene exprimieren
SE9900519D0 (sv) A method for the preparation of UHMWPE doped with an antioxidant and an implant made thereof
EE05110B1 (et) 3-(3-isopropl-5-metl-4H-1,2,4-triasool-4-l)ekso-8-asabitsklo[3.2.1]oktaani derivaadid, selliste derivaatide valmistamismeetodid, nende valmistamisel kasutatavad vahehendid, selliseid derivaatesisaldavad kompositsioonid ja kombinatsioonid ning
AU4195897A (en) Chlamydial vaccines and immunogenic compositions containing an outer membrane antigen and methods of preparation thereof
DK0743948T4 (da) Chromatografisk isolering af nucleinsyrer
WO2002010337A3 (en) Method of cloning porcine animals
AU5448600A (en) High early strength cement and additives and methods for making the same
IL149810A0 (en) Method of enhancing immune responses to herpes simplex virus vaccine
DE69736779D1 (de) Zusammensetzungen von rekombinanten papillomavirus vakzinen
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
MD970269A (en) Clavulanates
NO943374L (no) Psylliumholdig materialsammensetning
CA2283597A1 (en) Reduced cortisol conjugates
WO1999012945A3 (en) Hydrophobic glycosylamine derivatives, compositions, and methods for use
NZ330913A (en) Antigens for preventing and reducing parasite infection and disease
MX9701127A (es) Cemento modificado y composiciones de concreto.
EE200100329A (et) Bensisoksasoolid ja fenoonid, nende valmistamismeetod ja kasutamine ning kompositsioon ja selle valmistamismeetod

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties